

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY DOCKET NO. <b>6523-038</b>	APPLICATION NO <b>TBA</b>
	APPLICANT <b>Cheng et al.</b>	
	FILING DATE <b>September 4, 2003</b>	GROUP <b>TBA</b>

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>W</i>	A01	4,000,137	12/28/76	Dvonch et al.			
	A02	4,336,381	6/22/82	Nagata et al.			
	A03	4,861,759	8/29/89	Mitsuya et al.			
	A04	4,879,277	11/7/89	Mitsuya et al.			
	A05	4,916,122	4/10/90	Chu et al.			
	A06	4,963,533	10/16/90	de Clercq et al.			
	A07	5,047,407	9/10/91	Belleau et al.			
	A08	5,059,690	10/22/91	Zahler et al.			
	A09	5,071,983	12/10/91	Koszalka et al.			
	A10	5,179,104	1/12/93	Chu et al.			
	A11	5,185,437	2/9/93	Koszalka et al.			
	A12	5,204,466	4/20/93	Liotta et al.			
	A13	5,210,085	5/11/93	Liotta et al.			
	A14	5,248,776	9/28/93	Chu et al.			
	A15	5,532,246	7/02/96	Belleau et al.			
	A16	5,539,116	7/23/96	Liotta et al.			
	A17	5,587,480	12/24/96	Belleau et al.			
<i>W</i>	A18	6,350,753	2/26/02	Belleau et al.			

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>W</i>	B01	EP 206 497 B1	7/20/94	EP				
	B02	EP 302 760 B1	7/29/92	EP				
	B03	EP 337 713 A2	10/18/89	EPO				
	B04	EP 375 329 A2	6/27/90	EPO				
	B05	EP 382 526 A2	8/16/90	EPO				
	B06	EP 433 898 A	6/26/91	EPO				

B07	EP 494 119 A1	7/8/92	EPO				
B08	EP 515 144 A1	5/19/92	EPO				
B09	EP 515 156 A1	11/25/92	EP				
B10	EP 515 157 A1	11/25/92	EPO				
B11	EP 526 253 A1	2/3/93	EPO				
B12	GB 9009861.7	11/14/91	GB				
B13	GB 9100039.8	7/23/92	GB				
B14	GB 9109506.7	11/12/92	GB				
B15	GB 9109913.5	7/23/92	GB				
B16	GB 9111902.4	12/10/92	GB				
B17	WO 90/12023	10/18/90	PCT				
B18	WO 91/11186	8/8/91	PCT				
B19	WO 91/11186	8/8/91	PCT				
B20	WO 91/17159	11/14/91	PCT				
B21	WO 92/10496	6/25/92	PCT				
B22	WO 92/10497	6/25/92	PCT				
B23	WO 92/11852	7/23/92	PCT				
B24	WO 92/14743	9/3/92	PCT				
B25	WO 92/15308	9/17/92	PCT				
B26	WO 92/18517	10/29/92	PCT				
B27	WO 92/19246	11/12/92	PCT				
B28	WO 92/21676	12/10/92	PCT				

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Balzarini et al., 1986, "Potent and selective ant-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine", <i>Biochem Biophys Res Comm</i> 140(2):735-742.
C02	Belleau et al., 1989, "Design and activity of a novel class of nucleoside analogs effective against HIV-1", 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989.
C03	Carter et al., 1990, "Activities of (-)-carbovir and 3'azido-3'deoxythymidine against human immunodeficiency virus <i>in vitro</i> ", <i>Antimicrob Agents Chemother</i> 34(6):1297-1300.
C04	Chang et al., 1987, "Production of hepatitis B virus <i>in vitro</i> by transient expression of cloned HBV DNA in a hepatoma cell line", <i>EMBO J</i> 6(3):675-680.
C05	Chang et al., 1992, "Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication", <i>J Biol Chem</i> 267:13938-13942.

	C06	Chen and Cheng, 1989, "Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine", <i>J Biol Chem</i> 264(20):11934-11937.
	C07	chromatograph alleging to show that BCH-189 was separated into its individual enantiomers using a chiral triacetylcellulose column (see Third Supplemental Information Disclosure Statement under 37 C.F.R. § 1.56)
	C08	Chu et al., 1988, "An efficient total synthesis of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZDDU, CS-87) from <u>D</u> -mannitol", <i>Tetrahedron Letters</i> 29(42):5349-5352.
	C09	Chu et al., 1988, "Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells", <i>Biochem Pharmacol</i> 37(19):3543-3548.
	C10	Chu et al., 1989, "Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells", <i>J Med Chem</i> 32:612-617.
	C11	Cretton et al., 1991, "Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells", <i>Mol Pharmacol</i> 39:258-266.
	C12	Cretton et al., 1991, "Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in Rhesus monkeys", <i>Antimicrob Agents Chemother</i> 35(5):801-807.
	C13	Di Bisceglie et al., 1988, "Hepatocellular carcinoma", <i>Ann Intern Med</i> 108:390-401.
	C14	Doong et al., 1991, "Inhibition of the replication of hepatitis B virus <i>in vitro</i> by 2',3'-dideoxy-3'-thiacytidine and related analogues", <i>Proc Natl Acad Sci</i> 88:8495-8499.
v	C15	E.L. Eliel, <i>Stereochemistry of Carbon Compounds</i> 31-86 (1962)
h	C16	F.A. Farraye et al., "Preliminary Evidence that Azidothymidine does not Affect Hepatitis B Virus Infection in Acquired Immunodeficiency Syndrome (AIDS) Patients," <i>J. Med. Virol.</i> 29:266-67 (1989)
	C17	Furman et al., 1992, "The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the the (-) and (+) enantiomers of <i>cis</i> -5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine", <i>Antimicrob Agents Chemother</i> 36(12):2686-2692.
	C18	Ganem and Varmus, "The molecular biology of the hepatitis B virus", <i>Ann Rev Biochem</i> 56:651-693.
	C19	H. Haritani et al., "Effect of 3'-Azido-3'-Deoxythymidine on Replication of Duck Hepatitis B Virus <i>In Vivo</i> and <i>In Vitro</i> ," <i>J. Med. Virol.</i> 29:244-48 (1989)
	C20	H.E. Varmus, "A Growing Role for Reverse Transcription," <i>Nature</i> 299:204-205 (1982)
	C21	Jeong et al., 1993, "Asymmetric synthesis and biological evaluation of $\beta$ -L-(2R,5S)- and $\alpha$ -L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents", <i>J Med Chem</i> 36(2):181-195.
	C22	Kassianides et al., 1989, "Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine: A potential inhibitor of reverse transcriptase", <i>Gastroenterology</i> 97:1275-1280.
	C23	Krenitsky et al., 1983, "3'-amino-2',3'-dideoxyribonucleosides of some pyrimidines: Synthesis and biological activities", <i>J Med Chem</i> 26(6):891-895.
	C24	Lee et al., 1989, "In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus", <i>Antimicrob Agents Chemother</i> 33(3):336-339.

	C25	Lin et al., 1987, "Potent and selective <i>in vitro</i> activity of 3'-deoxythymidin-2'ene(3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus", <i>Biochem Pharmacol</i> 36(17):2713-2718.
✓	C26	M. Mahmoudian et al., "Enzymatic Production of Optically Pure (2 <i>R</i> - <i>cis</i> )-2'-deoxy-3'-thiacytidine (3TC, Lamivudine): A potent anti-HIV agent," <i>Enzyme Microb. Technol.</i> 15:749-55 (1993)
	C27	Matthes et al., 1990, "Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides", <i>Antimicrob Agents Chemother</i> 34(16):1986-1990.
	C28	Memorandum, 1988, "Progress in the control of viral hepatitis: Memorandum from a WHO meeting", <i>Bull WHO</i> 66(4):443-455.
	C29	Miller and Robinson, 1986, "Common evolutionary origin of hepatitis B virus and retroviruses", <i>Proc Natl Acad Sci</i> 83:2531-2535.
	C30	Mitsuya et al., 1985, "3'-azido-3'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus <i>in vitro</i> ", <i>Proc Natl Acad Sci</i> 82:7096-7100.
	C31	Mitsuya et al., 1987, "Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV", in <u>AIDS: Modern Concepts And Therapeutic Challenges</u> , Broder (ed.), pp. 303-333.
	C32	Mitsuya et al., 1990, "Molecular targets for AIDS therapy", <i>Science</i> 249:1533-1544.
	C33	Norbeck et al., 1989, "(±)-Dioxolane-T: A new 2',3'-dideoxynucleoside prototype with <i>in vitro</i> activity against HIV", <i>Tetrahedron Letters</i> 30(46):6263-6266.
	C34	Okabe et al., 1988, "Synthesis of the dideoxynucleosides ddC and CNT from glutamic acid, ribolactone, and pyrimidine bases", <i>J Org Chem</i> 53(20):4780-4786.
	C35	Richman et al., 1987, "The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex", <i>New Engl J Med</i> 317(4):192-197.
✓	C36	S.H. Wilen, <i>Tables of Resolving Agents and Optical Resolutions</i> 3-33 and 141-195 (1972)
	C37	Satsumabayashi et al., 1972, "The syntheses of 1,3-oxathiolan-5-one derivatives", <i>Bull Chem Soc Japan</i> 45:913-915.
	C38	Schinazi et al., 1992, "Activities of four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes", <i>Antimicrob Agents Chemother</i> 36(3):672-676.
	C39	Schinazi et al., 1992, "Insights into HIV chemotherapy", <i>AIDS Research and Human Retroviruses</i> 8(6):963-990.
	C40	Schinazi et al., 1992, "Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in Rhesus monkeys", <i>Antimicrob Agents Chemother</i> 36(11):2432-2438.
	C41	Schinazi et al., 1992, "Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of <i>cis</i> -5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine", <i>Antimicrob Agents Chemother</i> 36(11):2423-2431.
	C42	Schinazi et al., 1992, "Substrate specificity of <i>Escherichia coli</i> thymidine phosphorylase for pyrimidine nucleosides with-anti-human immunodeficiency virus activity", <i>Biochem Pharmacol</i> 44(2):199-204.
	C43	Sells et al., 1987, "Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA", <i>Proc Natl Acad Sci</i> 84:1009-1009.
	C44	Soudeyns et al., 1991, "Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog", <i>Antimicrob Agents Chemother</i> 35(7):1386-1390.

	C45	Sterzycki et al., 1990, "Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides", J Med Chem 33:2150-2157.
	C46	Storer et al., 1993, "The resolution and absolute stereochemistry of the enantiomers of <i>cis</i> -1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (BCH189): Equipotent anti-HIV agents", Nucleosides and Nucleotides 12(2):225-236.
	C47	Sureau et al., 1986, "Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with a cloned circular HBV DNA", Cell 47:37-47.
	C48	Tsurimoto et al., 1987, "Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA", Proc Natl Acad Sci 84:444-448.
	C49	Volk (ed.), 1982, "Essentials of Medical Microbiology", pp. 609-618.
	C50	Vorbruggen et al., 1981, "Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts", Chem Ber 114:1234-1255.
n	C51	W.H. Pirkle et al., "Chiral Stationary Phases for the Direct LC Separation of Enantiomers," ( <i>journal title and date unavailable</i> ); pp 73-127
	C52	Wilsomet et al., 1990, "A general method for controlling glycosylation stereochemistry in the synthesis of 2'-deoxyribose nucleosides", Tetrahedron Letters 13:1815-1818.
	C53	Wilson et al., 1993, "The synthesis and anti-HIV activity of pyrimidine dioxolanyl nucleosides", Bioorg Med Chem Letters 3(2):169-174.
	C54	Yokota et al., 1990, "Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro", Antimicrob Agents Chemother 34(7):1326-1330.
	C55	Zhu et al., 1991, "Cellular metabolism of 3'-azido-2',3'-dideoxyuridine with formation of 5'-O-diphosphohexose derivatives by previously unrecognized metabolic pathways for deoxyuridine analogs", Mol Pharmacol 38:929-938.
	C56	Skalski et al., 1993, "The biochemical basis for the differential anti-human immunodeficiency virus activity of two <i>cis</i> enantiomers of 2',3'-dideoxy-3'-thiacytidine. J Biol Chem. 268(31):23234-8
	C57	De Clercq E. 1995, "Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem. 38(14):2491-517. Review
	C58	Bastow et al. 1983, "Susceptibility of phosphonoformic acid-resistant herpes simplex virus variants to arabinosylnucleosides and aphidicolin. Antimicrob Agents Chemother. 1983 Jun;23(6):914-7

EXAMINER	<i>N. Cook</i>	DATE CONSIDERED	<i>6/25/05</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			